Connor, Clark & Lunn Investment Management (CC&L)’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-122,793
Closed -$3.87M 1715
2025
Q2
$3.87M Sell
122,793
-49,466
-29% -$1.59M 0.01% 657
2025
Q1
$5.64M Sell
172,259
-29,310
-15% -$1.04M 0.02% 472
2024
Q4
$7.29M Sell
201,569
-13,295
-6% -$468K 0.03% 390
2024
Q3
$6.7M Buy
214,864
+127,420
+146% +$3.98M 0.03% 371
2024
Q2
$2.34M Buy
87,444
+6,118
+8% +$177K 0.01% 609
2024
Q1
$2.77M Sell
81,326
-22,671
-22% -$675K 0.01% 583
2023
Q4
$3.01M Buy
103,997
+23,413
+29% +$621K 0.01% 565
2023
Q3
$2.22M Buy
80,584
+24,365
+43% +$742K 0.01% 590
2023
Q2
$1.69M Buy
56,219
+38,820
+223% +$1.36M 0.01% 651
2023
Q1
$630K Buy
17,399
+3,940
+29% +$152K ﹤0.01% 819
2022
Q4
$480K Buy
+13,459
New +$468K ﹤0.01% 872

Other funds holding SUPN